Infliximab produces a sustained and significant improvement in psoriasis over 50 weeks of continuous therapy.

Kristian Reich; F. O. Nestle; Ortonne Jp; Kim Papp; Robert J. Evans; Cynthia Guzzo; Shuangyue Li; L T Dooley; Christopher Em Griffiths

Back

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2006

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial

Kristian Reich, Frank O. Nestlé, Kim Papp, J.‐P. Ortonne, Yifang Wu, M Bala, Robert J. Evans, Cynthia Guzzo, Shuangyue Li, Lisa T. Dooley, Christopher Em Griffiths

Article2008

Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate-to-severe psoriasis over 54 weeks: the CRYSTEL study

Jean‐Paul Ortonne, Christopher Em Griffiths, E. Daudén, Robert Strohal, Deborah Robertson, Ronald Pedersen, C. Molta, Bruce Freundlich

Article2009

Indacaterol Once-Daily Provides Sustained 24-h Bronchodilation over 52 Weeks of Treatment in COPD.

Ronald E Dahl, P Kolman, DB Jack, Roger Owen, Benjamin Krämer, Mark Higgins

Article2009

Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study

E. Daudén, Christopher Em Griffiths, Ortonne Jp, Knud Kragballe, CT Molta, Deborah Robertson, Ronald Pedersen, Joanne Estojak, R. Boggs

Article2012

Does p40‐targeted therapy represent a significant evolution in the management of plaque psoriasis?

Christopher Em Griffiths, Giampiero Girolomoni